Liège, Belgium, 07 February 2017 – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women’s health, today announces that it has completed recruitment into the Phase III study of its product candidate Estelle®, a combined oral contraceptive based on Estetrol (E4) and Drospirenone (DRSP), in Europe and Russia.
Share it
Latest news
Mithra reaches milestone in estetrol skin study
8 April 2024
Mithra updates on its ongoing monetization process
28 March 2024